Casebia Therapeutics is at the forefront of the drive to turn the promise of gene editing into cures for patients. Casebia is a private, independent company focused on discovering and developing CRISPR/Cas9 therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease, blindness, hearing loss and heart disease. Our strong foundation – comprised of a large up-front financial commitment combined with a license to the foundational CRISPR/Cas9 patent estate – gives us the stability and flexibility to simultaneously pursue treatments for the patients of today and advance the CRISPR technologies of tomorrow. At Casebia, we have created an open, trusting, and collaborative environment where scientific discovery can thrive, and an inclusive, diverse culture that reflects the patients and families who depend on us. We operate in the innovation hubs of Cambridge, MA and San Francisco, CA
Launched with a $300 million financial commitment, Casebia is well-positioned to achieve its goals by tapping the considerable scientific and financial resources of its joint venture partners, Bayer and CRISPR Therapeutics. We believe our success will validate a new business model for translating emerging biotechnologies into life-saving and life-enhancing products.
Our current programs include treatments for Hemophilia A, Severe Combined Immunodeficiencies (SCID), Immunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome (IPEX) and several ophthalmological diseases.
Casebia is committed to exploring new strategic collaborations with biopharma companies, academic institutions, universities and other relevant organizations to accelerate and bolster our pipeline and R&D capabilities to optimize the accuracy, efficiency and safety of gene-editing technology.